FDA Approves Moderna's mRNA Flu Vaccine for Adults 50+
Edited by Casualplayhub News Editorial. Source: CBS New York Business. Casualplayhub News adds summary, context, and editorial framing while linking back to the original report.
The U.S. Food and Drug Administration has approved Moderna's first mRNA-based influenza vaccine, mFLUSIVA, for adults aged 50 and older, the company announced on Wednesday. The decision marks a significant milestone: it is the first time a flu vaccine using messenger RNA technology has received FDA authorization. This approval arrives after an initial period of regulatory resistance, though the agency ultimately concluded the vaccine's benefits outweigh potential risks for the older adult population.
Moderna, which cemented its reputation with the highly effective mRNA COVID-19 vaccine, has been working to adapt the same platform for seasonal influenza. The FDA's green light follows a rigorous review of clinical trial data showing that mFLUSIVA elicited a strong immune response against multiple flu strains. While the agency had earlier expressed concerns about certain aspects of the vaccine's safety profile, those issues were resolved through additional data and manufacturing adjustments, sources familiar with the process said.
In a statement, Moderna Chief Executive Stéphane Bancel called the approval "a testament to the ongoing potential of our mRNA platform" and emphasized the company's commitment to addressing unmet medical needs. The vaccine is designed to be updated annually, like traditional flu shots, but the mRNA approach allows for faster production and potentially better strain matching. Traditional flu vaccines rely on growing virus in chicken eggs, a process that takes months and sometimes yields lower efficacy against mismatched strains.
mFLUSIVA is specifically indicated for adults 50 and older, a group at higher risk for severe flu complications. The FDA's decision was based on a Phase 3 trial involving approximately 4,000 participants, which demonstrated that the vaccine was safe and induced antibody levels comparable to or exceeding those of existing flu vaccines. Common side effects included injection site pain, fatigue, and headache, consistent with other mRNA vaccines.
The approval comes at a time when the flu season remains unpredictable. The 2023-2024 season saw moderate to high activity, with the CDC estimating millions of cases and thousands of deaths. Health experts hope that the new mRNA vaccine could offer better protection, especially for older adults whose immune systems tend to respond less robustly to traditional vaccines. However, it remains to be seen whether mFLUSIVA will be more effective than existing options, as real-world data are not yet available.
Moderna plans to manufacture the vaccine at its facilities in Massachusetts and New Hampshire, with distribution expected to begin in time for the 2024-2025 flu season. Pricing details have not been announced, but the company has indicated it will be competitive with other enhanced flu vaccines, such as high-dose and adjuvanted shots. The vaccine will be administered as a single dose, and the company is exploring whether a two-dose regimen might be needed for certain populations.
The FDA's move also signals a broader shift in the regulatory landscape for mRNA vaccines. While the pandemic accelerated the platform's acceptance, the agency has maintained a cautious stance on its use for routine seasonal diseases. The approval of mFLUSIVA could pave the way for additional mRNA-based vaccines targeting other respiratory viruses, such as respiratory syncytial virus (RSV) and human metapneumovirus, which Moderna is also developing.
Public health officials have welcomed the approval, noting that the addition of an mRNA flu vaccine could help diversify the vaccine supply and reduce reliance on egg-based production. Dr. Amesh Adalja, an infectious disease expert at the Johns Hopkins Center for Health Security, commented, "This is a promising development. The mRNA platform has demonstrated its versatility, and having another option for flu prevention is valuable, especially for older adults who are most vulnerable."
However, some experts caution that the vaccine's long-term safety and efficacy in real-world settings remain to be established. The FDA has required Moderna to conduct post-marketing studies to monitor for rare adverse events, such as myocarditis, which was observed in young males after COVID-19 mRNA vaccination. No such signals were detected in the trial for mFLUSIVA, but the older age group may have a different risk profile.
For now, Moderna is racing to bring its flu vaccine to market, competing with established players like Sanofi and Seqirus, as well as emerging mRNA rivals like Pfizer-BioNTech, which is also developing an mRNA flu shot. The approval of mFLUSIVA represents a critical step in expanding the mRNA technology beyond COVID-19, and it positions Moderna to become a major player in the seasonal flu vaccine market.
Article commentary
This approval is a landmark for mRNA technology, demonstrating its flexibility beyond pandemic response. The initial regulatory pushback underscores the FDA's commitment to rigorous safety oversight, which is crucial for public trust. However, the real-world efficacy of mFLUSIVA compared to existing flu vaccines remains uncertain. Moderna will need to deliver on its promise of improved strain matching and production speed. The post-marketing surveillance requirements are prudent, given the history of rare adverse events with mRNA vaccines. While this is a step forward, the flu vaccine market is crowded, and older adults already have enhanced options. The true test will be whether mFLUSIVA can reduce hospitalizations and deaths more effectively than current standards.